J Clin Oncol:R-CHOP program plus lynamine can further improve prognostics in newly diagnosed DLBCL patients

The lysodami and cyclophosphamide, amycin, chrysanthromycin, and strong pine (R-CHOP) showed good results in untreated patients with diffuse large B-cell lymphoma (DLBCL), especially for active B-cell-like (ABC) subtypes.
Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412 was a randomized Phase II study comparing the efficacy of R2CHOP and R-CHOP in untreated DLBCL.
in this trial, newly diagnosed International Prognostic Index (IPI) ≥2, ECOG Performance Status≤2 of phase II large block-IV DLBCL patients were randomly assigned to the R2CHOP group and R-CHOP group for a total of 6 cycles.
end point of the disease is the progress-free lifetime (PFS) in ABC-DLBCL patients.
secondary endpoints include total mitigation rate (ORR), full mitigation rate (CR), and total survival rate (OS).
recruited 349 patients, 280 of whom could be included in the analysis (145 in R2CHOP group and 135 in R-CHOP group): 94 in ABC-DLBCL patients, 122 in B-cell-like DBCL in the birth center, 18 bits in untypeable, 46 cases that were not clear.
the baseline characteristics were well balanced between the PFS and OS groups in all patients, with a medium age of 66 years (range 24-92 years), 70% of patients with stage IV disease, and 34%, 43% and 24% of patients with IPI scores of 2, 3 and 4/5, respectively.
bone marrow inhibition is more common in the R2CHOP group.
orR and CR rates in the R-CHOP group and R2CHOP group were 92% and 68% vs 97% (p-0.06) and 73% (p-0.43), respectively.
3.0 years of PFS and OS mid-level follow-up in ABC-DLBCL patients, and a 34% lower risk of disease progressity or death in the R2CHOP group than R-CHOP (risk ratio of 0.66,95% CI 0.43-1.01), 3 years PFS and OS are higher (PFS: 73% vs 61%, p=0.03; OS:83% vs 75%, p=0.05).
, the study showed that the prognostic prognostics of newly diagnosed DLBCL patients, including ABC-DLBCL patients, were significantly improved.